point is that whereas TNF has a deleterious role in some aspects of the pathophysiology of MS, on balance, peripheral blockade of TNF with antibodies known to improve diseases such as rheumatoid arthritis and Crohn's disease leads to a worsening of MS. The new data now show that a TNF-producing DC is critical for induction of CD8 + T cells that attack myelin in EAE.
Another cell type, in addition to the Tip-DC, that is able to present myelin to the CD8 + T cells is the oligodendrocyte, especially after MHC class I molecules are induced 7 . TNF and interferon-γ are two of the mediators produced in the inflammatory milieu in the brain during EAE and MS that can induce the expression of MHC or HLA class I molecules on oligodendrocytes. This widens the multifaceted and Janus-like opposing roles of TNF in the pathophysiology of MS.
Goverman's group continues to explore the pathophysiology of the CD8 + T cell response even different myelin antigens but also the widening immunity can now extend from the CD4 lineage to autoreactive T cells from the CD8 lineage with receptors for myelin. The mechanism involves the presentation of myelin to CD8 + T cells via the Tip-DCs 1 .
The role of TNF thus becomes ever more complicated. TNF is ordinarily thought of as a proinflammatory mediator in autoimmune disease, but in MS, attempts to block TNF with either antibody to or soluble receptors for TNF have lead to worsening of the disease 10 . The role of the Tip-DC, which produces TNF 11 , thus makes the role of this cytokine in MS ever more nuanced. TNF does have a pathological role in MS through the induction of VCAM-1, the receptor for the integrin α 4 . Blockade of the integrin α 4 ameliorates EAE, and the monoclonal antibody to the integrin α 4 known as natalizumab is the most effective approved drug in the MS arsenal 12 . The only safe conclusion at this 1 . There is an abundance of evidence suggesting that in cancer, MDSCs negatively regulate antitumor immunity and promote tumor metastasis and angiogenesis 2 . MDSCs express the cell-surface markers Gr-1 and CD11b but lack features of mature macrophages and dendritic cells (DCs) and have been categorized into two main subpopulations with either a monocytic morphology (M-MDSCs) or a polymorphonuclear morphology (PMN-MDSCs) 3 . Although both populations expand in tumorbearing hosts, PMN-MDSCs are consistently the dominant population. The origin and fate of PMN-MDSCs, however, has remained unclear. In a report published in this issue of Nature Immunology, Youn et al. show that in
Myeloid-cell differentiation redefined in cancer

Thomas A Wynn
The differentiation of monocytes is altered in cancer, which results in the unexpected conversion of a large proportion of monocytic myeloid-derived suppressor cells into polymorphonuclear myeloid-derived suppressor cells.
tumor-bearing mice, inflammatory monocytes with an M-MDSC phenotype differentiate into PMN-MDSCs instead of differentiating into macrophages or DCs 4 . Therefore, the authors identify M-MDSCs as the main precursors of these important tumor-promoting cells. Mechanistically, the study shows that M-MDSCs acquire morphological features of PMN-MDSCs through the transcriptional silencing of the gene encoding retinoblastoma, a transcriptional regulator that controls cellular proliferation and differentiation.
In mice, M-MDSCs have low expression of Gr-1 and have a CD11b + Ly6C hi Ly6G -phenotype. They are highly immunosuppressive and exert their regulatory activity mostly in an antigen-nonspecific manner 5 . In contrast, PMNMDSCs are Gr-1 + and are characterized by a CD11b + Ly6C lo Ly6G + phenotype. These cells are moderately immunosuppressive and suppress immune responses mainly by antigen-specific mechanisms. The PMN-MDSC subset is greatly expanded in tumor-bearing hosts, whereas only slightly more M-MDSCs are detected in such hosts 3 . Surprisingly, despite the fact that PMNMDSCs dominate in tumor-bearing mice, Youn et al. find, by a variety of techniques (including incorporation of the thymidine analog BrdU), that only the M-MDSC population undergoes substantial proliferation in vitro and in vivo 4 . Because it is difficult to reconcile that finding with the 'preferential' population expansion of PMN-MDSCs, the authors hypothesize that the large population of PMN-MDSCs might in fact be derived from the M-MDSC pool.
To investigate their hypothesis, the authors isolate M-MDSCs from normal and tumorbearing mice and monitor their phenotype in vitro over several days. Surprisingly, they find that after only a few days in culture, nearly 40% of the sorted M-MDSC derived from tumorbearing mice downregulate Ly6C expression and upregulate expression of the marker Ly6G, providing the first evidence that M-MDSCs transform into PMN-MDSCs (Fig. 1) . During that in vitro culture, M-MDSCs transition from a promyelocyte phenotype into an obvious neutrophil morphology, and this progression follows the conventional hematopoietic steps of neutrophil differentiation 6 . Notably, the newly differentiated PMN-MDSCs are able to inhibit T cell responses, in confirmation of their suppressive ability. In contrast, in similar experiments with Ly6C hi monocytes isolated from normal non-tumor-bearing mice, the cells follow the normal developmental path volume 14 number 3 mArCH 2013 nature immunology the role of Rb1 in monocyte differentiation, the authors isolate bone marrow monocytes from Rb1-deficient mice and their wild-type littermates and culture them in vitro with the cytokine GM-CSF and tumor explant supernatants. As expected, only a small fraction of the Rb1-expressing Ly6C hi monocytes acquire the Ly6G marker and morphological features of PMN cells. In contrast, nearly 20% of the monocytes isolated from Rb1-deficient mice acquire a PMN-like morphology. Conversely, after overexpression of Rb1 in M-MDSCs, their differentiation into PMN-MDSC is much lower. Surprisingly, however, the PMN cells isolated from Rb1-deficient mice do not have suppressive activity. Nevertheless, EL4 tumor cells grow much faster in Rb1-deficient mice, which suggests that the PMN-like cells probably acquire suppressive characteristics in the tumor microenvironment. In future studies, it will be important to identify the factors in the tumor microenvironment or in tumor explant supernatants that regulate the conversion of PMN cells into PMN-MDSCs. In any case, these exciting studies suggest that lower expression of Rb1 in M-MDSCs is responsible for their conversion into PMN-MDSCs in tumor-bearing mice.
The authors next seek to determine whether epigenetic changes, including histone modifications, are responsible for the silencing of Rb1. To investigate this, they isolate PMN-MDSCs from tumor-bearing mice, culture them in vitro with several inhibitors of all histone deacetylases (HDACs) and determine if Rb1 expression is restored. Strikingly, they observe substantial upregulation of Rb1 expression in cultures in which HDACs are inhibited. Conversely, in similar experiments with M-MDSCs isolated from tumor-bearing mice, the HDAC inhibitors block their conversion into Ly6G-expressing PMN-MDSCs and restore the development of macrophages and DCs. Further investigation suggests that HDAC-2, but not HDAC-1, is responsible for the silencing of Rb1 in PMN-MDSCs. Thus, in future studies it will be exciting to investigate if inhibitors of HDAC-2 could be used to diminish the number of PMN-MDSCs and improve antitumor immunity in cancer 11 .
Finally, to determine if similar mechanisms operate in humans, Youn et al. isolate CD14 + HLA-DR neg-lo monocytes (which represent the M-MDSC population) from the bone marrow of patients with multiple myeloma and determine whether they convert into PMN-MDSCs at a higher frequency than do M-MDSCs isolated from healthy controls 4, 12 . Impressively, they find nearly 8% of the M-MDSCs differentiate into CD66b + cells with a PMN morphology after only 5 days of culture in GM-CSF and conditioned medium from
The authors also find a much lower abundance of total and phosphorylated Rb1 in the spleens of tumor-bearing mice and that isolated Gr1 + cells have much lower expression of Rb1. Detailed studies show that Rb1 expression is selectively lower in the PMN-MDSC population than in all other lymphoid populations, including M-MDSCs, mature PMN cells and DCs.
Given the different expression of Rb1 in M-MDSCs versus PMN-MDSCs, the authors next seek to determine whether Rb1 controls MDSC proliferation or possibly regulates the conversion of M-MDSCs into PMN-MDSCs. Using immunofluorescence staining techniques to monitor Rb1 expression in tumorbearing mice, they observe heterogeneous expression of Rb1 in M-MDSCs and monocytes. However, they find that M-MDSCs with low expression of Rb1 are consistently the subset that acquires the PMN-MDSC phenotype. In contrast, monocytes with high expression of Rb1 maintain their normal developmental fate and differentiate into macrophages or DCs.
To delineate the role of Rb1 in PMN-MDSC development, the authors compare Rb1-deficient and Rb1-expressing mice and determine that although there is little difference between Rb1-expressing mice and non-tumor-bearing Rb1-deficient mice in the number of splenic monocytes, the PMN populations of non-tumor-bearing Rb1-deficient expand more than those of Rb-1-expressing mice, consistent with published reports 9 4 . In comparing both cell types, they find lower expression of several members of the retinoblastoma gene family 'preferentially' in the PMN-MDSC subset. These genes are of interest because proteins of the retinoblastoma family, including Rb1, p107 and p130, function as transcriptional regulators and control the cell cycle, cellular proliferation and differentiation 8 . Thus, although it was previously thought that M-MDSCs and PMN-MDSCs develop along divergent developmental pathways, this interesting study suggests that MDSC development is altered in cancer, an alteration that results in the conversion of a large proportion of M-MDSCs into PMN-MDSCs. Consequently, there is much more overlap between these two suppressor cell populations than was previously thought. One concern about these studies, however, is the finding that the downmodulation of Rb1 expression in PMN cells does not endow them with suppressive activity. Therefore, it will be important to identify the tumor-associated factors or inflammatory mediators expressed in vivo that direct the conversion of M-MDSCs into classical PMN-MDSCs with suppressive activity. It will also be important to identify the factors that control the recruitment of PMNMDSCs to the tumor and the transcriptional programs that control their activation in situ. Once this pathway is fully elucidated, the various signals could become targets of future therapeutics. Indeed, preliminary data in this study suggest that HDAC-2-specific inhibi- Changing course by lymphocyte lineage redirection
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The fate of T cells differentiating into the CD4 or CD8 lineage is typically fixed when cells leave the thymus. However, CD4 + helper T cells can be reprogrammed to develop into CD4 + CD8a + cytotoxic T lymphocytes in the gut.
T lymphocytes (CTLs) in the gut that naturally lack expression of ThPOK 3 . Through the use of an elegant series of genetic models, they show that these cells arise from ThPOK + CD4 + T cells that downregulate ThPOK expression after leaving the thymus and trafficking to the gut, which leads to the derepression of the CTL gene program. In a companion paper, Reis et al. show that the conversion of CD4 + helper T cells into CD4 + CD8α + CTLs begins with upregulation of the expression of Runx3, which subsequently silences the gene encoding ThPOK 4 . Those molecular events culminate in the reprogramming of these cells from a helper T cell fate to a cytotoxic T cell fate and loss of colitogenic potential. Collectively, these two papers show that converted CD4 + CD8α + CTLs are present in the gut at steady state as intraepithelial lymphocytes in normal mice, where they lie dormant until they are 'called to arms' by engagement of their CD4-TCR complexes in the presence of IL-15. The discovery that such reprogramming events occur in vivo under physiological conditions challenges the concept of irrevocable CD4-versus-CD8 lineage 'commitment' . Furthermore, the finding that reprogramming of splenic CD4 + T cells is potentiated only after cells reach the gut raises new questions about how the intestinal environment affects the differentiation and function of T cells in situ.
It has been shown that experimental manipulation of ThPOK expression can alter the stability of the gene program of helper T cells and lead to derepression of the cytotoxic program 5, 6 . However, the ability of MHC class IIrestricted CD4 + helper T cells to become cytotoxic effector T cells under physiological conditions is remarkable because it is essentially a renunciation of the fate imposed during development in the thymus. Specifically, the generation of CD4 + CD8α + CTLs from ThPOK + helper T cells involves the acquisition of a 'license to kill' by T cells that have been thymically selected against such a function. Commitment can be defined as the inability of a cell to respond to external stimuli that attempt to impose a different fate. The generegulatory network that drives T cell development in the thymus is deep, layered and hierarchical and includes a series of 'checkpoints' for which death is the default choice. These developmental features effectively prevent the generation of dangerous effector T cells. Therefore, it is critical that these gene programs, once installed, be 'locked down' , and this is achieved by mechanisms such as cross-regulatory feedback loops and epigenetic silencing. Indeed, establishment of the CD4 + T cell lineage involves the silencing of the gene encoding Runx3 by ThPOK, whereas
